Account
Inquiry
Amble Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. With its unique molecular structure featuring PEG modification, this peptide demonstrates enhanced water solubility and biological activity.
The peptide appears as white powder with 99.9% purity, supplied in research-grade packaging. Clinical studies indicate Amble Tirzepatide shows superior efficacy in glucose control and weight management compared to single receptor agonists, making it a valuable compound for metabolic disorder research.
In clinical trials, Amble Tirzepatide demonstrated significant weight reduction results, with average losses of 15-20.9% body weight at different dosage levels over 72 weeks. These findings highlight its potential for obesity-related research applications.
As a research chemical, Amble Tirzepatide represents an important advancement in dual agonist therapy development. Its mechanism combines the beneficial effects of both GIP and GLP-1 pathways, offering researchers new opportunities to study metabolic regulation.
